A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Combination of DFMO and Sulindac to Decrease the Rate of Recurrence of Adenomatous Polyps in the Colon

Trial Profile

A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Combination of DFMO and Sulindac to Decrease the Rate of Recurrence of Adenomatous Polyps in the Colon

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2015

At a glance

  • Drugs Eflornithine (Primary) ; Sulindac (Primary)
  • Indications Colorectal cancer; Intestinal polyps
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Mar 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
    • 20 Apr 2011 Planned End Date changed to 1 Dec 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top